Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study

References

• Jeffcoate WJ, Vileikyte L, Boyko EJ, et al. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41(4):645–652.
   PubMed Web of Science ®Google Scholar
• Nussbaum SR, Carter MJ, Fife CE, et al. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. Value Health. 2018;21(1):27–32.
   PubMed Web of Science ®Google Scholar
• Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann NY Acad Sci. 2018;1411(1):153–165.
   PubMed Web of Science ®Google Scholar
• Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3S–21S.
   PubMed Web of Science ®Google Scholar
• Martin J. Preparing for the transition to value-based reimbursement: what you need to know. J Med Pract Manage. 2017;32(5):313–316.
   PubMedGoogle Scholar
• DiDomenico LA, Orgill DP, Galiano RD, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: a prospective, randomised, multi-centre clinical trial in 80 patients. Int Wound J. 2018;15(6):950–957.
   PubMed Web of Science ®Google Scholar
• Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009;9:115.
   PubMed Web of Science ®Google Scholar
• Beckert S, Witte M, Wicke C, et al. A new wound-based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients. Diabetes Care. 2006;29(5):988–992.
   PubMed Web of Science ®Google Scholar
• Carter MJ. Why is calculating the “true” cost-to-heal wounds so challenging? Adv Wound Care. 2018;7(11):371–379.
   Web of Science ®Google Scholar
• Coerper S, Beckert S, Küper MA, et al. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing-analysis of a single-center cohort of 704 diabetic patients. J Diabetes Complicat. 2009;23(1):49–53.
   PubMed Web of Science ®Google Scholar
• Hicks CW, Canner JK, Mathioudakis N, et al. The society for vascular surgery Wound, Ischemia, and foot Infection (WIfI) classification independently predicts wound healing in diabetic foot ulcers. J Vasc Surg. 2018;68(4):1096–1103.
   PubMed Web of Science ®Google Scholar
• Carter MJ, Gilligan AM, Waycaster CR, et al. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers. J Med Econ. 2017;20(3):253–265.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics, Centers for Disease Control and Prevention. National Vital Statistics System: Deaths: final data for 2013; [cited 2019 July 1]. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.pdf.
   Google Scholar
• Dowsett C, Newton H. Wound bed preparation: TIME in practice. Wounds UK. 2005;1:58–70.
   Google Scholar
• Carter MJ, Fife CE. Clinic visit frequency in wound care matters: data from the US wound registry. J Wound Care. 2017;26(Sup1):S4–S10.
   PubMedGoogle Scholar
• Wilcox JR, Carter MJ, Covington S. Frequency of debridements and time to heal: a retrospective cohort study of 312 744 wounds. JAMA Dermatol. 2013;149(9):1050–1058.
   PubMed Web of Science ®Google Scholar
• Hill E. Time is on your side: coding on the basic of time. Fam Pract Manag. 2008;15(9):17–21.
   PubMedGoogle Scholar
• SalaryExpert. Wound care physician salary; [cited 2018 July 5]. Available from:https://www.salaryexpert.com/salary/job/wound-care-physician/united-states.
   Google Scholar
• Indeed. Wound care nurse salaries in the United States; [cited 2018 July 5]. Available from: https://www.indeed.com/salaries/Wound-Care-Nurse-Salaries.
   Google Scholar
• The Centers for Medicare and Medicaid Services. ASP Drug Pricing Files July 2019 Update; [cited 2019 July 5]. Available from:https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles.html.
   Google Scholar
• The Centers for Medicare and Medicaid Services. 2019. Clinical diagnostic laboratory fee schedule; [cited 2019 July 14]. Available from:https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files-Items/19CLABQ1.html.
   Google Scholar
• Barshes NR, Chambers JD, Cohen J, et al. Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. J Vasc Surg. 2012;56(4):1015–1024.e1.
   PubMed Web of Science ®Google Scholar
• Akhavan S, Ward L, Bozic KJ. Time-driven activity-based costing more accurately reflects costs in arthroplasty surgery. Clin Orthop Relat Res. 2016;474(1):8–15.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid. Inpatient Charge Data, FY2016; [cited 2019 July 14]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Inpatient2016.html.
   Google Scholar
• Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations and estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30(6):549–556.
   PubMed Web of Science ®Google Scholar
• Carter MJ. Cost-effectiveness research in wound care: definitions, approaches, and limitations. Ostomy Wound Manage. 2010;56(11):68–85.
   PubMedGoogle Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Keel G, Savage C, Rafiq M, et al. Time-driven activity-based costing in health care: a systematic review of the literature. Health Policy. 2017;121(7):755–763.
   PubMed Web of Science ®Google Scholar
• Stockl K, Vanderplas A, Tafesse E, et al. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care. 2004;27(9):2129–2134.
   PubMed Web of Science ®Google Scholar
• Briggs AD, Wolstenholme J, Blakely T, et al. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Popul Health Metr. 2016;14:17. DOI:10.1186/s12963-016-0085-1
   PubMedGoogle Scholar
• Romero Prada M, Roa C, Alfonso P, et al. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabet Foot Ankle. 2018;9(1):1480249.
   PubMed Web of Science ®Google Scholar
• Nherera LM, Woodmansey E, Trueman P, et al. Estimating the clinical outcomes and cost differences between standard care with and without cadexomer iodine in the management of chronic venous leg ulcers using a Markov model. Ostomy Wound Manage. 2016;62(6):26–40.
   PubMed Web of Science ®Google Scholar
• Guest JF, Weidlich D, Singh H, et al. Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US. J Wound Care. 2017;26(Sup1):S12–S24.
   PubMedGoogle Scholar
• Cazzell SM, Lange DL, Dickerson JE, Jr, et al. The management of diabetic foot ulcers with porcine small intestine submucosa tri-layer matrix: a randomized controlled trial. Adv Wound Care. 2015;4(12):711–718.
   Web of Science ®Google Scholar
• Guest JF, Singh H, Vowden P. Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK. J Wound Care. 2018;27(3):136–144.
   PubMed Web of Science ®Google Scholar
• Samsell B, McLean J, Cazzell S, et al. Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes. J Wound Care. 2019;28(Sup9):S14–S26.
   PubMedGoogle Scholar
• Allenet B, Parée F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab. 2000;26(2):125–132.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health. 2012;15(6):812–820.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15(6):843–850.
   PubMed Web of Science ®Google Scholar